Phase I Study of Combination of Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Mar 2018
At a glance
- Drugs Bevacizumab (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer
- Focus Adverse reactions
- 01 Mar 2018 Planned End Date changed from 1 Apr 2019 to 1 Apr 2021.
- 01 Mar 2018 Planned primary completion date changed from 1 Apr 2019 to 1 Apr 2020.
- 01 Mar 2018 Status changed from recruiting to active, no longer recruiting.